Can Novavax Win over Vaccine-Hesitant?

  • By Park Se-mi

    February 11, 2022 12:39

    Novavax's COVID-19 vaccine will be given to high-risk groups such as unvaccinated elderly people and nursing home residents from next Monday.

    The government hopes that the vaccine, which works like widely accepted flu or Hepatitis B vaccines, will persuade the vaccine-hesitant to get jabbed at last.

    Unvaccinated adults can also get the vaccine if they make a booking for daily leftovers, health authorities said Thursday.

    Two doses of Nuvaxovid, which was approved by the Ministry of Food and Drug Safety last month, will be given three weeks apart just like mRNA vaccines from Pfizer and Moderna. A third dose will be given three months after the second.


    Nuvaxovid is expected to persuade those who are still hesitating to get vaccinated for fear of adverse effects because it is a synthetic antigen-based vaccine of the same kind long used to prevent flu, hepatitis B and cervical cancer. About 3.41 million adults remain unvaccinated.

    From Monday, authorities plan to visit the homes of elderly shut-ins and the severely handicapped to give them the vaccine if they want. Other unvaccinated people can make bookings for leftovers on various apps.

    Mixing any other previously-administered vaccines with Nuvaxovid will be permitted. "It's possible for anyone, who has been vaccinated with Pfizer or Moderna vaccines for a first or second jab but has stopped going further due to adverse effects like myocarditis to take Nuvaxovid for as second or third dose." In that case, they need to consult a doctor in advance.

    Those who had with two doses of Nuvaxovid should then get their first booster three months later, but they can go with an mRNA vaccine if they want.

    "Adverse effects, which were mostly mild to moderate, occurred among less than one percent of Nuvaxovid recipients but disappeared one to three days later." Two doses proved 89.7 percent effective in preventing COVID in clinical tests in the U.K. and 90.4 percent in the U.S. The vaccine was also 100 percent effective in preventing severe cases or deaths.

    • Copyright © Chosunilbo &
    Previous Next
    All Headlines Back to Top